Evaluation of hGM-CSF/hTNFα surface-modified prostate cancer therapeutic vaccine in the huPBL-SCID chimeric mouse model by Shouhua Lai et al.
JOURNAL OF HEMATOLOGY
& ONCOLOGY
Lai et al. Journal of Hematology & Oncology  (2015) 8:76 
DOI 10.1186/s13045-015-0175-8LETTER TO THE EDITOR Open AccessEvaluation of hGM-CSF/hTNFα surface-
modified prostate cancer therapeutic vaccine
in the huPBL-SCID chimeric mouse model
Shouhua Lai1†, Zhiyong Huang2†, Yunting Guo1†, Yunqin Cui1, Lei Wang1, Weifeng Ren1, Furong Ying1, Hui Gao1,
Lingxia He1, Tieli Zhou1*, Jiegen Jiang1* and Jimin Gao1*Abstract
To validate its efficacy in the context of the human immune system, a novel therapeutic vaccine of hGM-CSF/hTNFα
surface-modified PC-3 cells against human prostate cancer was evaluated in the human peripheral blood
lymphocytes-severe combined immunodeficiency (huPBL-SCID) chimeric mouse model. The hGM-CSF or/and
hTNFα modified vaccines inhibited prostate cancer growth effectively so as to prolong the mouse survival significantly.
The splenocytes from the hGM-CSF/hTNFα vaccine-inoculated mice showed the strongest tumor-specific cytotoxicity
against PC-3 cells and the highest production of IFNɤ. These features indicated that type 1 protective immune
response was induced efficiently against human prostate cancer and further enhanced through synergetic adjuvant
effects of hGM-CSF and hTNFα.
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Prostate cancer is currently the second leading cause of
cancer-related death in elderly men and likely develops
into androgen-independent at advanced stages, which
is refractory to conventional treatments. Cancer vaccine
is a rational option for the treatment of androgen-
independent prostate cancer [1]. Cancer immunotherapy
is getting more and more important, remarkably evi-
denced by recent checkpoint blockade or chimeric anti-
gen receptor-engineered T cell-based clinical trials with
the impressive efficacy in different types of metastatic
cancers [2, 3].
Through simultaneous immobilization of streptavidin-
tagged bioactive GM-CSF and TNFα on the biotinylated
surface of cancer cells, we previously showed that the
resultant cancer vaccines could induce a strong anti-
tumor T cell immunity [4–7]. In the current study,* Correspondence: wyztli@163.com; jiegen_jiang@yahoo.com;
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creativecommons.org/publicdomain/zero/1.0/human peripheral blood lymphocytes-severe combined
immunodeficiency (huPBL-SCID) model was utilized
to mimic the human immune system for evaluating
the efficacy of these therapeutic vaccines. The mate-
rials and methods used in this study are detailed in
Additional file 1.
We demonstrated that SA-hGM-CSF or/and SA-
hTNFα could be efficiently immobilized on the biotinyl-
ated surface of ethanol-fixed PC-3 cells (Additional file 2)
and SA-hGM-CSF or/and SA-hTNFα immobilized on
the PC-3 cells still retained their bioactivity (Additional
file 3).
The PC-3 cells inoculated subcutaneously in nonob-
ese diabetic/severe combined immunodeficiency (NOD/
SCID) mice were found to maintain their original tumori-
genicity so as to spread into the blood (Additional file 4).
There was no phenomenon of immune leakage [8] in
NOD/SCID mice used in this study. The activity of
natural killer (NK) cells in the NOD/SCID mice was
dramatically reduced by injection of anti-asialo-GM1
antibody (Additional file 5).distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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CD45+ cells in peripheral blood and human CD45+ cells
in spleen of huPBL-SCID mice. IHC staining revealed
many human CD4+ and CD8+ lymphocytes present in
spleen and fewer human CD4+ and CD8+ lymphocytes
in liver tissue 8 weeks after transfer of huPBL. The re-
sults indicated that human T lymphocytes were suc-
cessfully engrafted and homed in appropriate lymphoid
organs of huPBL-SCID mice (Additional files 6 and 7).
We tested therapeutic effects of different PC-3 cell
vaccines modified with hGM-CSF and/or hTNFα on
human prostate cancer in the huPBL-SCID mouse
model. Compared with other cancer vaccines, the hGM-
CSF/hTNFα doubly modified cancer vaccine significantly
inhibited prostate cancer growth in terms of tumor
weight (Fig. 1a) and size (Fig. 1b) and effectively pro-
longed the mice survival (Fig. 1c).
There were more human leukocytes and CD4+ or
CD8+ lymphocytes residing in the lymph nodes in the
hGM-CSF/hTNFα doubly modified group than in other
groups 8 weeks after vaccination (Additional file 8).
Similarly, more human CD4+ or CD8+ T lymphocytes























































Fig. 1 Therapeutic effects of hGM-CSF or/and hTNFα modified PC-3 cell va
After inoculation with PC-3 prostate cancer cell vaccine, huPBL-SCID mice w
and 14. We collected and weighted the tumors in the mice died at differen
data at the time point on day 60 in the PBS control group because all mic
size of cross-sectional area of the tumors in each group along with the tim
the day of injecting PC-3 cancer cells as the starting point and drew surviv
experimentshGM-CSF/hTNFα doubly modified group than in other
groups (Fig. 2a, b), indicating that the hGM-CSF/hTNFα
doubly modified PC-3 cell vaccine could enhance its
anti-tumor immunity by increasing the infiltration of
human T lymphocytes into the tumors.
We finally analyzed the tumor-specific cytotoxicity of
cytotoxic T lymphocytes (CTL) in the spleen and re-
vealed that the GM-CSF/TNFα doubly modified vaccine
did establish a stronger tumor-specific T cell immunity
than other PC-3 cell vaccines (Fig. 2c). The supernatant
from in vitro splenocyte culture in the GM-CSF/TNFα
doubly modified group had the highest production of
PC-3-specific IFNγ (Fig. 2d). Both results indicated that
type 1 protective immunity was induced against the
human prostate cancer.
Therefore, our current study provided a solid foun-
dation for potential clinical application of this novel
hGM-CSF/hTNFα surface-modified prostate cancer the-
rapeutic vaccine. This unique approach can be easily
adopted to generate a personalized whole cancer cell
vaccine from individual autologous cancer cells, there-
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ccines on human prostate cancer in the huPBL-SCID mouse model.
ere treated i.p. with PC-3 cancer cell vaccines or PBS on days 0, 7,
t time points or those still living on day 60 (p < 0.05). There were no
e died before/on day 56 (a). In addition, we drew a curve of the mean
e period (b). Meanwhile, we recorded the time of all mice death with
al curves (p < 0.05) (c). The results represented one of three separate
Fig. 2 Immunohistochemical staining analysis of lymphocytes in tumor tissue and assessment of PC-3-specific cytotoxicity and IFNγ in spleen.
Immunohistochemical staining analyzed CD4+ or CD8+ lymphocytes in the tumor tissues from huPBL-SCID mice 8 weeks after vaccination.
The images of immunohistochemical staining were shown with ×200 magnification. Tumor tissues from different groups were stained with
anti-hCD4 or anti-hCD8 antibody (a), and the quantitative analysis of the images was performed with integrated optic density (b). For PC-3-
specific cytotoxicity assay, spleen cells were isolated on day 21 after tumor injection from each experimental group. Effector cells were stimulated by
recombinant human IL-2 and mitomycin-treated PC-3 cancer cells. The supernatants were collected for the non-radioactive cytotoxicity assay (c).
For quantification of IFNγ by ELISA, splenocytes were isolated from experimental mice 7 days after the last tumor vaccination and incubated with
hIL-2 and mitomycin-treated PC-3 cancer cells for 48 h. The supernatants were collected for the measurement of IFNγ by ELISA (d). Error bars
represented the SEM in both (c) and (d)
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Additional file 1: Materials and methods.
Additional file 2: Flow cytometric analysis of the modification
efficiency of streptavidin (SA)-tagged hGM-CSF and/or hTNFα on
the surface of ethanol-fixed and biotinylated PC-3 prostate cancer
cell vaccine. Ethanol-fixed PC-3 cells were biotinylated and then incubated
with SA-hGM-CSF, SA-hTNFα, or both as described before. The presence of
hGM-CSF or/and hTNFα was assessed with allophycocyanin (APC)-labeled
anti-hGM-CSF (1:400) or/and fluorescein isothiocyanate (FITC)-labeled
anti-hTNFα (1:100) monoclonal antibodies for flow cytometric analysis.
Ethanol-fixed PC-3 cells were used as control.Additional file 3: Bioactive assays of hGM-CSF and hTNFα
immobilized on the surface of ethanol-fixed PC-3 prostate cancer
cell vaccine. Membrane fractions were prepared from the hGM-CSF/
hTNFα doubly modified PC-3 cancer cell vaccine as described in
materials and methods. (A) Bioactive assay of hGM-CSF immobilized on
the surface of ethanol-fixed PC-3 cell vaccine. The proliferative activity
of membrane-conjugated hGM-CSF was assessed on TF-1 cells with
SA-hGM-CSF/SA-hTNFα un-modified PC-3 cell vaccine as negative
control. (B) Bioactive assay of hTNF-α immobilized on the surface of
ethanol-fixed PC-3 cell vaccine. The cytotoxic activity of membrane-
conjugated hTNFα was assessed on L929 cells with hGM-CSF/hTNFα
un-modified PC-3 cell vaccine as negative control. Data were shown as
the mean ± SEM of triplicates.
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peripheral blood from NOD/SCID mice with anti-hPSMA and
anti-HLA. Tumor tissues and peripheral blood were isolated on the 30th
and 60th day to prepare single cell suspensions. The presence of PSMA
and HLA (human leukocyte antigen) was assessed with APC-labeled
anti-hPSMA (1:100) and FITC-labeled anti-hHLA (1:200) monoclonal
antibodies, respectively, for flow cytometric analysis. The LNCaP prostate
cancer cells were used as a positive control because they could secrete
PSA and express PSMA. (A) The single cell suspension from tumor tissue
on day 30 with APC-labeled anti-hPSMA. (B) The LNCaP prostate cancer
cells. (C) The single cell suspension from tumor tissue on day 30 with
FITC-labeled anti-hHLA. (D) The blood from PC-3 inoculated NOD/
SCID mice on day 30 with FITC-labeled anti-hHLA. (E) The white cells
from PC-3 inoculated NOD/SCID mice on day 60 with FITC-labeled
anti-hHLA.
Additional file 5: Screen for the immune “leakage” phenomenon of
NOD/SCID mice and detection of the levels of NK cells before and
after injection of NK cell inhibitor GM1. (A) Concentration of IgG in
peripheral blood serum of NOD/SCID mice. The immune “leakage”
phenomenon was screened by the levels of IgG through ELISA kit
(Beyotime) in 25 NOD/SCID mice with standard and blank controls
(data from the controls not shown). The concentration of IgG lower than
10 μg/ml was defined as no immune leakage. (B) The changes of CD122
levels in peripheral blood of NOD/SCID mice before and after injection
of NK cell inhibitor anti-asialo-GM1 antibody. CD122 was assessed with
FITC-labeled anti-CD122 (1:200) monoclonal antibody for flow cytometric
analysis. Left: CD122 level before injection of NK cell inhibitor anti-
asialo-GM1 antibody; middle: CD122 level after injection of NK cell
inhibitor anti-asialo-GM1 antibody; right: comparison of CD122
levels before and after injection of NK cell inhibitor anti-asialo-GM1
antibody.
Additional file 6: Flow cytometric analysis of human lymphocytes
in the peripheral blood and spleen tissue of huPBL-SCID mice after
huPBL transplantation. (A) The presence of CD45+, CD8+, or CD4+ cells
was assessed respectively with phycoerythrin (PE)-labeled anti-hCD45,
PE-Cy7-labeled anti-hCD8, and PE-Cy7-labeled anti-hCD4 monoclonal
antibodies for flow cytometric analyses. (B) Flow cytometric analysis of
human CD45+ cells in the spleen tissue of huPBL-SCID mice 8 weeks after
huPBL transplantation. Spleen was isolated from huPBL-SCID 8 weeks
after huPBL transplantation and single cell suspensions were prepared
from the isolated spleen. The presence of CD45+ cells was assessed with
PE-labeled anti-hCD45 monoclonal antibody through a flow cytometer.
NOD/SCID mice without huPBL transplantation were used as the negative
controls.
Additional file 7: Immunohistochemical staining of spleen and liver
tissues from huPBL-SCID mice 8 weeks after huPBL transplantation.
The images of immunohistochemical staining were shown with ×200
magnification. The spleen and liver tissues from huPBL-SCID mice were
stained with anti-hCD4 or anti-hCD8 antibody (A), and the quantitative
analysis of the images was performed with integrated optic density (B).
The spleen and liver tissues from NOD/SCID mice without huPBL
transplantation were used as negative controls.
Additional file 8: Immunohistochemical staining analysis of
the lymph node tissues from huPBL-SCID mice 8 weeks after
vaccination. The images of immunohistochemical staining were shown
with ×200 magnification. Lymph node tissues from different groups were
stained with rat anti-hCD45 (A), anti-hCD4 (B), or anti-hCD8 antibody (C).
The quantitative analysis of those images was carried out with integrated
optic density (D).
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